AstraZeneca Q2 Profit Down, Revenues Climb; Updates FY21 Outlook - Quick Facts

AstraZeneca (AZN.L,AZN) reported Thursday that its second-quarter profit before tax fell 20 percent to $764 million from last year's $961 million. Earnings per share were $0.42, down 27 percent from $0.58 a year ago.

Core earnings per share were $0.90, down 6 percent.

Total revenue for the second quarter climbed 31 percent to $8.22 billion from last year's $6.28 billion. Revenues grew 25 percent at constant currency rates.

Excluding the contribution from the pandemic COVID-19 vaccine, revenue increased 17% in the quarter to $7.33 billion.

Further, the company announced an unchanged first interim dividend of $0.90 or 64.8 pence per ordinary share.

Looking ahead, AstraZeneca updated its full-year 2021 guidance to reflect the contribution of Alexion in the year. Total revenue is now expected to increase by a low-twenties percentage, accompanied by a faster growth in Core earnings per share to $5.05 to $5.40.

The previous expectations issued by both companies earlier in 2021 remain broadly in line with current assumptions and underpin the updated guidance.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT